Our study found that early use of dapagliflozin in post-AMI heart failure significantly reduced sST2 and NT-proBNP levels, suggesting that dapagliflozin may improve myocardial fibrosis and remodeling following early myocardial infarction. The gene discussed is NPPB; the disease is myocardial infarction.